Galleri® Test
Multi-Cancer Early Detection (MCED)
Approved/CommercialCommercial
Key Facts
About GRAIL
GRAIL is a mission-driven company leveraging next-generation sequencing, population-scale clinical studies, and advanced machine learning to detect cancer early when it may be more treatable. Its clinical program has enrolled over 300,000 participants, and its Galleri test is at the forefront of the MCED category. The company is publicly traded and is focused on commercializing Galleri, expanding clinical utility evidence, and pursuing partnerships to integrate its test into healthcare systems globally.
View full company profileTherapeutic Areas
Other Multi-Cancer Early Detection (MCED) Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Cancer Detection | Personalis | Research |
| ELSA-seq / OverC™ Multi-Cancer Detection Blood Test | Burning Rock Biotech | Clinical Validation |